Trials (May 2018)

Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I): a randomised controlled trial to examine the impact of an intensive lifestyle intervention consisting of a low-energy diet and physical activity on body weight and metabolism in early type 2 diabetes mellitus: study protocol for a randomized controlled trial

  • Shahrad Taheri,
  • Odette Chagoury,
  • Hadeel Zaghloul,
  • Sara Elhadad,
  • Salma Hayder Ahmed,
  • Omar Omar,
  • Sherryl Payra,
  • Salma Ahmed,
  • Neda El Khatib,
  • Rasha Abou Amona,
  • Katie El Nahas,
  • Matthew Bolton,
  • Henem Chaar,
  • Noor Suleiman,
  • Amin Jayyousi,
  • Mahmoud Zirie,
  • Ibrahim Janahi,
  • Wahiba Elhag,
  • Abdulla Alnaama,
  • Abduljaleel Zainel,
  • Dahlia Hassan,
  • Tim Cable,
  • Mary Charlson,
  • Martin Wells,
  • Abdulla Al-Hamaq,
  • Samya Al-Abdulla,
  • Abdul Badi Abou-Samra

DOI
https://doi.org/10.1186/s13063-018-2660-1
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Type 2 diabetes mellitus (T2DM) and obesity are syndemic and will have a significant impact on affected individuals and healthcare services worldwide. Evidence shows that T2DM remission can be achieved with significant weight loss in those who are younger with early diabetes and requiring fewer medications for glycaemic control. DIADEM-I aims to examine the impact of an intensive lifestyle intervention (ILI) using a low-energy diet (LED) meal replacement approach combined with physical activity in younger individuals with early T2DM. Methods The planned study is an ongoing, non-blinded, pragmatic, randomised controlled, parallel-group trial examining the impact of an LED-based ILI on body weight and diabetes remission in younger (18–50 years) T2DM individuals with early diabetes (≤ 3-year duration). The ILI will be compared to usual medical care (UMC). The primary outcome will be weight loss at 12 months. Other key outcomes of interest include diabetes remission, glycaemic control, diabetes complications, cardiovascular health, physical activity, mental health, and quality of life. It is planned for the study to include 138 subjects for assessment of the primary outcome. Safety will be assessed throughout. Discussion If DIADEM-I demonstrates a clinically significant effect for younger individuals with early T2DM, it will inform clinical guidelines and services of the future for management of T2DM. Trial registration ISRCTN: ISRCTN20754766 (date assigned: 7 June 2017); ClinicalTrials.gov, ID: NCT03225339 Registered on 26 June 2017.

Keywords